BIOAVAILABILITY IN CLINICAL EVALUATION OF DRUGS

[1] ARIENS EJ, 1964, MOLECULAR PHARMACOLO, V1, P197

[2] BARR W H, 1969, Drug Information Bulletin, V3, P27

[3] THERAPEUTIC NONEQUIVALENCE OF OXYTETRACYCLINE CAPSULES [J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1969, 208 (07): : 1189 - &

[4] CLARK AJ, 1937, HEFFTERS HDB EXPERIM, V4

[5] DILLER W, 1965, ARZNEI-FORSCHUNG, V15, P1274

[6] DOST FH, 1967, ARZNEI-FORSCHUNG, V17, P772

[7] DOST FH, 1968, GRUNDLAGEN PHARMAKOK, P156

[8] FEINBERG M, 1970, HOSP FORMUL MANAG, V5, P8

[9] GIOVANNINI M, 1962, ANTIBIOTICA 1, V1, P410

[10] LAMY P, 1969, PHARM TIMES, V35, P32

[1] ARIENS EJ, 1964, MOLECULAR PHARMACOLO, V1, P197

[2] BARR W H, 1969, Drug Information Bulletin, V3, P27

[3] THERAPEUTIC NONEQUIVALENCE OF OXYTETRACYCLINE CAPSULES [J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1969, 208 (07): : 1189 - &

[4] CLARK AJ, 1937, HEFFTERS HDB EXPERIM, V4

[5] DILLER W, 1965, ARZNEI-FORSCHUNG, V15, P1274

[6] DOST FH, 1967, ARZNEI-FORSCHUNG, V17, P772

[7] DOST FH, 1968, GRUNDLAGEN PHARMAKOK, P156

[8] FEINBERG M, 1970, HOSP FORMUL MANAG, V5, P8

[9] GIOVANNINI M, 1962, ANTIBIOTICA 1, V1, P410

[10] LAMY P, 1969, PHARM TIMES, V35, P32